 |
|
Monoclonal Antibody Therapy in the Treatment of Non-Hodgkin Lymphoma
Steven L. McCune, MD,PhD;
Jon P. Gockerman, MD;
David A. Rizzieri, MD
JAMA. 2001;286:1149-1152.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Monoclonal antibodies are revolutionizing the treatment of many illnesses. Some patients with coronary artery disease, Crohn disease, solid organ transplants, rheumatoid arthritis, or cancer have already experienced benefits from these engineered proteins. Monoclonal antibodies typically either harness the patient's own immune system to fight disease or suppress an errant immune system. Table 1 lists the monoclonal antibodies currently approved by the Food and Drug Administration (FDA); more than 50 others are in active clinical trials around the world. Monoclonal antibodies are currently used by cardiologists, gastroenterologists, nephrologists, and rheumatologists as well as oncologists. In this article, we focus on the use of monoclonal antibodies for the treatment of patients with non-Hodgkin lymphoma (NHL).
Table appears in full text version.
|
|
|
|
Table. Food and Drug Administration-Approved Therapeutic Monoclonal Antibodies
|
|
|
An estimated 56 000 people in the United States will develop NHL this year leading to more than . . . [Full Text of this Article]
Common Mechanisms of Action and Adverse Effects
Monoclonal Antibody Therapy
Monoclonal Antibodies Linked to Radioisotopes or Other Toxins
Monoclonal Antibodies in Combination With Other Modalities
Limitations
Future Directions and Summary
Author Affiliations: Duke University Medical Center, Department of Medicine, Division of Oncology and Bone Marrow Transplantation, Durham, NC.
RELATED ARTICLE
September 12, 2001
JAMA. 2001;286(10):1249-1250.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Noncovalent functionalization of carbon nanotubes for highly specific electronic biosensors
Chen et al.
Proc. Natl. Acad. Sci. USA 2003;100:4984-4989.
ABSTRACT
| FULL TEXT
|
